Nowadays, multiple immune checkpoint inhibitors that block programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) are used for the treatment of multiple cancers like melanoma, kidney and non-small-cell lung carcinomas, etc. (10). Here, PDCD1 is linked to melanoma.